逸達生物科技 Foresee Pharmaceuticals Co., Ltd.

Press Release

Date
Title
2022-05-31
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
2022-04-04
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
2022-02-23
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
2021-05-26
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
2021-03-28
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
2021-03-04
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
2020-12-24
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
2020-11-17
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China
2020-10-09
Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA
2020-09-17
Foresee Pharmaceuticals to Present at the 2020 Fanconi Anemia Scientific Symposium

Total 23 ( 10 records per page )　　　　Next　　Go page